Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Primary Myelofibrosis 2Myeloproliferative Disorders 2Recurrence 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

ruxolitinib 6Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5Cytarabine 5fludarabine phosphate 4Whole-Body Irradiation 4Methotrexate 4Daunorubicin 4Thioguanine 3Tacrolimus 3Etoposide 3Early Intervention, Educational 3Cyclophosphamide 3ponatinib 2parsaclisib 2nilotinib 2merphos 2luspatercept 2fludarabine 2fedratinib 2anagrelide 2Tretinoin 2Therapeutics 2Psychiatric Rehabilitation 2Mitoxantrone 2Filgrastim 2Cyclosporins 2Cyclosporine 2Busulfan 2Asparaginase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Myeloproliferative Disorders × parsaclisib × Clear all
NCT04551066 2025-10-21

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Incyte Corporation

Phase 3 Terminated
252 enrolled 18 charts
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04551053 2025-10-02

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Incyte Corporation

Phase 3 Terminated
177 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡